ASH 2018: New data presented on synergistic action of LIMK inhibitors with BCR-ABL TKIs

At the 60th American Society of Hematology Congress, Pr Thorsten Braun presented the work performed by the Leukemia Translational Laboratory, Saint Louis Hospital , Paris, on selective LIM Kinase 1/2 inhibitors for combination treatment of BCR-ABL1 Acute Lymphoblastic Leukemia.

This new data includes positive results from in vitro experiments and in vivo models, obtained when combining administration of CEL_Amide with BCR-ABL1 Tyrosine Kinase Inhibitors including nilotinib.

It reinforces the rationale for looking into LIM Kinase inhibition as synergistic therapeutic agents with TKIs targeting TKRs upstream of the Rho-GTPase pathway, such as FLT3, C-KIT and BCR-ABL.

The ASH 2018 Poster can downloaded here Poster BCR-ABl LIMK ASH 2018

read more